TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Safety and Effectiveness of the Hydrus Aqueous Implant for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery, A Prospective, Multicenter, Randomized, Controlled Clinical Trial
Brief Summary: This clinical trial is a prospective, randomized, controlled, multicenter, study. After informed consent is obtained, patients will be evaluated for eligibility based on glaucoma severity, eye health, and visual acuity. Following successful screening, use of all topical glaucoma medications will be stopped for a period of "washout" to establish a qualifying medication-free intraocular pressure (IOP) value. Clinical follow up will be scheduled over the course of the 24 month study, and examinations will be repeated to monitor eye health. At the 1 and 2 year follow up, those patients on ocular hypotensive medications will be instructed to washout, and then have the diurnal (IOP taken in the morning, mid-day, and afternoon in the same day) IOP evaluation. Annual follow up will occur up to 5 years. The primary effectiveness endpoint is a decrease in diurnal IOP from baseline compared to the 24 months diurnal IOP following medication washout.


Options:
A: Arm Label: Trabectome-IOL; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Trabectome-IOL | Arm Label: Trab-IOL; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Trab-IOL | Intervention Type: PROCEDURE; Name: Trabectome-IOL; Assigned to Arm(s): Trabectome-IOL | Intervention Type: PROCEDURE; Name: Trab-IOL; Assigned to Arm(s): Trab-IOL
B: Arm Label: Trabeculectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Trabeculectomy with mitomycin C | Arm Label: Implant; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Baerveldt implant | Intervention Type: PROCEDURE; Name: Baerveldt implant; Assigned to Arm(s): Implant | Intervention Type: PROCEDURE; Name: Trabeculectomy with mitomycin C; Assigned to Arm(s): Trabeculectomy
C: Arm Label: InnFocus MicroShunt; Type: EXPERIMENTAL; Interventions: Device: InnFocus MicroShunt | Arm Label: Trabeculectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Glaucoma Surgery | Intervention Type: PROCEDURE; Name: Glaucoma Surgery; Assigned to Arm(s): Trabeculectomy | Intervention Type: DEVICE; Name: InnFocus MicroShunt; Assigned to Arm(s): InnFocus MicroShunt
D: Arm Label: Hydrus Aqueous Implant (Treatment); Type: EXPERIMENTAL; Interventions: Device: Hydrus Aqueous Implant | Arm Label: Cataract Surgery (Control); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Cataract surgery | Intervention Type: DEVICE; Name: Hydrus Aqueous Implant; Assigned to Arm(s): Hydrus Aqueous Implant (Treatment) | Intervention Type: PROCEDURE; Name: Cataract surgery; Assigned to Arm(s): Cataract Surgery (Control)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Therapy to Prevent Sexual Pain in Menopausal Survivors of Breast Cancer
Brief Summary: The purpose of this protocol is to determine whether pain with sexual intercourse can be reduced in menopausal, breast cancer survivors and to evaluate the effectiveness of a non-hormonal therapy (Lidocaine Liquid) vs. a placebo liquid in reducing pain.

The investigators hypothesize that the pain arises in the vulvar vestibule. The investigators predict that the localized use of lidocaine will be more efficacious than use of placebo liquid.


Options:
A: Intervention Type: PROCEDURE; Name: Issue of information booklet; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness-Based Stress Reduction | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mindfulness-Based Stress Reduction; Assigned to Arm(s): 1
C: Arm Label: Minimal intervention control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Internet-based cognitive behavioral therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-based cognitive behavioral therapy. | Intervention Type: BEHAVIORAL; Name: Internet-based cognitive behavioral therapy.; Assigned to Arm(s): Internet-based cognitive behavioral therapy
D: Arm Label: Topical liquid lidocaine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Topical liquid lidocaine, Drug: Topical saline | Arm Label: Topical Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Topical liquid lidocaine, Drug: Topical saline | Intervention Type: DRUG; Name: Topical liquid lidocaine; Assigned to Arm(s): Topical Saline, Topical liquid lidocaine | Intervention Type: DRUG; Name: Topical saline; Assigned to Arm(s): Topical Saline, Topical liquid lidocaine

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sublingual Misoprostol Versus Standard Surgical Care for the Treatment of Incomplete Abortion
Brief Summary: Women diagnosed with incomplete abortion in this health facility will be randomized to receive one of the following regimens: 400 mcg sublingual misoprostol in one dose or standard surgical treatment (MVA). The investigators hypothesize that treatment of incomplete abortion with misoprostol using 400 mcg administered sublingually will be as effective as surgical evacuation.


Options:
A: Arm Label: Single dose group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: Repeated dose group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Repeated dose group, Single dose group
B: Arm Label: pitocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: mifepristone and oxytocin | Arm Label: misopristol; Type: ACTIVE_COMPARATOR; Interventions: Drug: mifepristone and misopristol | Intervention Type: DRUG; Name: mifepristone and misopristol; Assigned to Arm(s): misopristol | Intervention Type: DRUG; Name: mifepristone and oxytocin; Assigned to Arm(s): pitocin
C: Arm Label: Misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: Manual vacuum aspiration (MVA); Type: ACTIVE_COMPARATOR; Interventions: Procedure: surgery Manual vacuum aspiration (MVA) | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: PROCEDURE; Name: surgery Manual vacuum aspiration (MVA); Assigned to Arm(s): Manual vacuum aspiration (MVA)
D: Arm Label: misoprostol plus mifepristone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol, Drug: Mifepristone | Arm Label: misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): misoprostol, misoprostol plus mifepristone | Intervention Type: DRUG; Name: Mifepristone; Assigned to Arm(s): misoprostol plus mifepristone

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sublingual Misoprostol Versus Standard Surgical Care for the Treatment of Incomplete Abortion
Brief Summary: Women diagnosed with incomplete abortion in this health facility will be randomized to receive one of the following regimens: 400 mcg sublingual misoprostol in one dose or standard surgical treatment (MVA). The investigators hypothesize that treatment of incomplete abortion with misoprostol using 400 mcg administered sublingually will be as effective as surgical evacuation.


Options:
A: Arm Label: Misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: Manual vacuum aspiration (MVA); Type: ACTIVE_COMPARATOR; Interventions: Procedure: surgery Manual vacuum aspiration (MVA) | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: PROCEDURE; Name: surgery Manual vacuum aspiration (MVA); Assigned to Arm(s): Manual vacuum aspiration (MVA)
B: Arm Label: surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: surgery | Arm Label: misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): misoprostol | Intervention Type: PROCEDURE; Name: surgery; Assigned to Arm(s): surgery
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: misoprostol | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Device: Dilapan-S, vitamin B-12 | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Dilapan-S, vitamin B-12; Assigned to Arm(s): 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: MIFEPRISTONE 200 mg and misoprostol 400 µg | Intervention Type: DRUG; Name: MIFEPRISTONE 200 mg and misoprostol 400 µg; Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sublingual Misoprostol Versus Standard Surgical Care for the Treatment of Incomplete Abortion
Brief Summary: Women diagnosed with incomplete abortion in this health facility will be randomized to receive one of the following regimens: 400 mcg sublingual misoprostol in one dose or standard surgical treatment (MVA). The investigators hypothesize that treatment of incomplete abortion with misoprostol using 400 mcg administered sublingually will be as effective as surgical evacuation.


Options:
A: Intervention Type: DRUG; Name: Doxycycline; Assigned to Arm(s): N/A
B: Arm Label: surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: surgery | Arm Label: misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): misoprostol | Intervention Type: PROCEDURE; Name: surgery; Assigned to Arm(s): surgery
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: MIFEPRISTONE 200 mg and misoprostol 400 µg | Intervention Type: DRUG; Name: MIFEPRISTONE 200 mg and misoprostol 400 µg; Assigned to Arm(s): 1
D: Arm Label: Misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: Manual vacuum aspiration (MVA); Type: ACTIVE_COMPARATOR; Interventions: Procedure: surgery Manual vacuum aspiration (MVA) | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: PROCEDURE; Name: surgery Manual vacuum aspiration (MVA); Assigned to Arm(s): Manual vacuum aspiration (MVA)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Immediate Postplacental Insertion of Intrauterine Devices at Time of Cesarean Delivery: A Randomized Clinical Trial
Brief Summary: This is a randomized controlled trial among women who deliver by cesarean at UNC Women's Hospital and desire an Intrauterine Device (IUD) for contraception postpartum. After consenting, women will be randomized to receive an IUD at time of cesarean delivery or at a postpartum visit 4-8 weeks later. After randomization, subjects will be given a choice of the Mirena® IUD or the Paragard® IUD. Data collection will occur at baseline, delivery, the 4-8 week postpartum visit, and 2 follow-up encounters at 3 and 6 months. We hypothesize that women who receive an IUD at the time of cesarean will be more likely to use an IUD 6 months later than women who plan on receiving an IUD 4-8 weeks after delivery.


Options:
A: Arm Label: 6 weeks interval insertion; Type: OTHER; Interventions: Other: 6 weeks interval insertion | Arm Label: Immediate insertion; Type: EXPERIMENTAL; Interventions: Other: Immediate insertion | Intervention Type: OTHER; Name: Immediate insertion; Assigned to Arm(s): Immediate insertion | Intervention Type: OTHER; Name: 6 weeks interval insertion; Assigned to Arm(s): 6 weeks interval insertion
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Etonogestrel contraceptive implant | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etonogestrel contraceptive implant | Intervention Type: DRUG; Name: Etonogestrel contraceptive implant; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Etonogestrel contraceptive implant; Assigned to Arm(s): 2
C: Arm Label: postplacental insertion after cesarean; Type: EXPERIMENTAL; Interventions: Device: Levonorgestrel-releasing intrauterine system (LNG-IUS) | Arm Label: delayed insertion group; Type: ACTIVE_COMPARATOR; Interventions: Device: Levonorgestrel-releasing intrauterine system (LNG-IUS) | Intervention Type: DEVICE; Name: Levonorgestrel-releasing intrauterine system (LNG-IUS); Assigned to Arm(s): postplacental insertion after cesarean | Intervention Type: DEVICE; Name: Levonorgestrel-releasing intrauterine system (LNG-IUS); Assigned to Arm(s): delayed insertion group
D: Arm Label: Interval IUD Placement; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Immediate Postplacental IUD placement; Type: EXPERIMENTAL; Interventions: Device: Immediate Postplacental Placement of an IUD during cesarean delivery | Intervention Type: DEVICE; Name: Immediate Postplacental Placement of an IUD during cesarean delivery; Assigned to Arm(s): Immediate Postplacental IUD placement

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Open-labelled, Controlled, Parallel Group Study to Assess the Efficacy and Safety of MUTAFLOR in 3 Weeks Treatment for Immunity Improvement in Preterm Infants With 1 Year Follow-up Period
Brief Summary: EcN has been registered as a medical drug under the brand name Mutaflor® SUSPENSION in Ukraine in 2010. Indications for its clinical use are acute diarrhea in infants and toddlers including those on tube feeding tube, diarrhea in children, prophylactics of pathological colonization in newborns including premature newborns, and improvement of immunity in newborns (mature and premature).

The aim of this trial was to observe efficacy and safety of Mutaflor® SUSPENSION use for immunity improvement in preterm newborn infants


Options:
A: Arm Label: Group I; Type: N/A; Interventions: N/A | Arm Label: Group II; Type: N/A; Interventions: N/A
B: Arm Label: Test group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotic yogurt | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotic yogurt; Assigned to Arm(s): Test group | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo group
C: Intervention Type: DRUG; Name: Mixture of probiotic bacteria and prebiotic oligosaccharide; Assigned to Arm(s): N/A
D: Arm Label: Bifidobacterium animalis lactis Bl-04; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Bifidobacterium lactis Bl-04, Biological: Rhinovirus | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo, Biological: Rhinovirus | Intervention Type: DIETARY_SUPPLEMENT; Name: Bifidobacterium lactis Bl-04; Assigned to Arm(s): Bifidobacterium animalis lactis Bl-04 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Rhinovirus; Assigned to Arm(s): Bifidobacterium animalis lactis Bl-04, Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mindfulness-based Therapy For the Treatment of Chronic Tinnitus: A Randomized Controlled Pilot Study
Brief Summary: In the present randomized waiting-list-controlled study the investigators examined a specific manualized mindfulness-based therapeutic approach in the treatment of chronic tinnitus.


Options:
A: Arm Label: Internet-based self-help; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-based guided self-help for tinnitus | Arm Label: Discussion forum group; Type: ACTIVE_COMPARATOR; Interventions: Other: Internet discussion forum | Intervention Type: BEHAVIORAL; Name: Internet-based guided self-help for tinnitus; Assigned to Arm(s): Internet-based self-help | Intervention Type: OTHER; Name: Internet discussion forum; Assigned to Arm(s): Discussion forum group
B: Arm Label: TRT / EMDR; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: TRT / CBT | Arm Label: TRT / CBT; Type: ACTIVE_COMPARATOR; Interventions: Other: TRT / EMDR | Intervention Type: OTHER; Name: TRT / EMDR; Assigned to Arm(s): TRT / CBT | Intervention Type: BEHAVIORAL; Name: TRT / CBT; Assigned to Arm(s): TRT / EMDR
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive behavioral therapy | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Waiting group | Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Waiting group; Assigned to Arm(s): 2
D: Arm Label: Mindfulness-based therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Mindfulness-based therapy | Arm Label: Treatment after waiting time; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment after waiting time | Intervention Type: BEHAVIORAL; Name: Mindfulness-based therapy; Assigned to Arm(s): Mindfulness-based therapy | Intervention Type: BEHAVIORAL; Name: Treatment after waiting time; Assigned to Arm(s): Treatment after waiting time

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Medication Adherence in Kidney Transplant Recipients Using Automated Reminders and Provider Notification
Brief Summary: Novel wireless technology has created inexpensive tools that allow both accurate monitoring of adherence to pills as well as real-time interventions such as automated reminders in the event of a missed dose. In this study, the investigators will use Vitality GlowCaps, an electronic pill bottle. These pill bottles provide an unbiased assessment of pill bottle opening and a valid approach to verifying self-administered pill taking, reflecting not only daily use but also patterns of drug use and timing. At the prescribed times, bottle will electronically transmit whether a subject opened the pill cap to take the immunosuppressant medication via a built-in transmitter to the central server. The investigators will randomize participants to usual care, customized reminders, and customized reminders paired with provider notification in the event of low adherence.

The investigators' aim: To improve immunosuppression (IS) medication adherence in kidney transplant recipients.

The investigators' hypotheses: a) Automated reminders will improve adherence to immunosuppression compared to usual care, and b) Automated reminders, paired with provider notification about patients with poor adherence, will improve adherence to immunosuppression compared to usual care.


Options:
A: Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: mHealth Intervention; Type: EXPERIMENTAL; Interventions: Other: mHealth Intervention | Intervention Type: OTHER; Name: mHealth Intervention; Assigned to Arm(s): mHealth Intervention
B: Arm Label: Medication Dosage Reminders; Type: EXPERIMENTAL; Interventions: Device: Vitality GlowCaps | Arm Label: Medicaiton Dosage Reminders + Coordinator Support; Type: EXPERIMENTAL; Interventions: Device: Vitality GlowCaps | Arm Label: Usual Care with GlowCap; Type: OTHER; Interventions: Device: Vitality GlowCaps | Intervention Type: DEVICE; Name: Vitality GlowCaps; Assigned to Arm(s): Medicaiton Dosage Reminders + Coordinator Support, Medication Dosage Reminders, Usual Care with GlowCap
C: Arm Label: Teen Pocket PATH® Mobile Application; Type: EXPERIMENTAL; Interventions: Other: Teen Pocket PATH® Mobile Application | Arm Label: Control Group: Standard of Care; Type: OTHER; Interventions: Other: Control Group: Standard of Care | Intervention Type: OTHER; Name: Teen Pocket PATH® Mobile Application; Assigned to Arm(s): Teen Pocket PATH® Mobile Application | Intervention Type: OTHER; Name: Control Group: Standard of Care; Assigned to Arm(s): Control Group: Standard of Care
D: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Mentoring group; Type: EXPERIMENTAL; Interventions: Behavioral: Peer Mentoring, Behavioral: e-Communication with mentor | Intervention Type: BEHAVIORAL; Name: Peer Mentoring; Assigned to Arm(s): Mentoring group | Intervention Type: BEHAVIORAL; Name: e-Communication with mentor; Assigned to Arm(s): Mentoring group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Blood Pressure Control and Compliance to Treatment in Hypertensive Patients With Metabolic Syndrome: a Study Based on Home Blood Pressure Telemonitoring
Brief Summary: The purpose of this study is to assess whether, in patients at high cardiovascular risk (hypertension with metabolic syndrome), long-term (1-year) blood pressure control is most effective when based on home blood pressure telemonitoring and on the feedback to the patient by the doctor between visits, or when based only on blood pressure determination during quarterly office visits.


Options:
A: Arm Label: remote monitoring; Type: EXPERIMENTAL; Interventions: Device: heart failure remote patient monitoring system | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: heart failure remote patient monitoring system; Assigned to Arm(s): remote monitoring
B: Arm Label: MSU; Type: EXPERIMENTAL; Interventions: Procedure: MSU | Arm Label: OCCM; Type: ACTIVE_COMPARATOR; Interventions: Procedure: OCCM | Intervention Type: PROCEDURE; Name: MSU; Assigned to Arm(s): MSU | Intervention Type: PROCEDURE; Name: OCCM; Assigned to Arm(s): OCCM
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-Directed Weight Loss Program | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Call-Center Directed (CCD) Weight Loss Program | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: In-Person Directed (IPD) Weight Loss Program | Intervention Type: BEHAVIORAL; Name: Call-Center Directed (CCD) Weight Loss Program; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: In-Person Directed (IPD) Weight Loss Program; Assigned to Arm(s): 3 | Intervention Type: BEHAVIORAL; Name: Self-Directed Weight Loss Program; Assigned to Arm(s): 1
D: Arm Label: Home blood pressure telemonitoring; Type: N/A; Interventions: N/A | Arm Label: Conventional blood pressure measurement; Type: N/A; Interventions: N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Blood Pressure Control and Compliance to Treatment in Hypertensive Patients With Metabolic Syndrome: a Study Based on Home Blood Pressure Telemonitoring
Brief Summary: The purpose of this study is to assess whether, in patients at high cardiovascular risk (hypertension with metabolic syndrome), long-term (1-year) blood pressure control is most effective when based on home blood pressure telemonitoring and on the feedback to the patient by the doctor between visits, or when based only on blood pressure determination during quarterly office visits.


Options:
A: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Generic Nudge; Type: EXPERIMENTAL; Interventions: Behavioral: Nudge | Arm Label: Optimized nudge; Type: EXPERIMENTAL; Interventions: Behavioral: Nudge | Arm Label: Optimized nudge plus AI Chat Bot; Type: EXPERIMENTAL; Interventions: Behavioral: Nudge | Intervention Type: BEHAVIORAL; Name: Nudge; Assigned to Arm(s): Generic Nudge, Optimized nudge, Optimized nudge plus AI Chat Bot
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Cell Phone Intervention | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Cell Phone Intervention; Assigned to Arm(s): 1
C: Arm Label: Control, Not hypertensive; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Text messages, hypertensive; Type: EXPERIMENTAL; Interventions: Behavioral: Text messaging | Arm Label: No text messages, hypertensive; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Text messaging; Assigned to Arm(s): Text messages, hypertensive
D: Arm Label: Home blood pressure telemonitoring; Type: N/A; Interventions: N/A | Arm Label: Conventional blood pressure measurement; Type: N/A; Interventions: N/A

Answer: D